Healthcare Industry News: gout
News Release - May 13, 2010
Nuon Therapeutics Names Lee Rauch Chief Executive OfficerSAN MATEO, Calif.--(HSMN NewsFeed)--Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced today that it has named Lee M. Rauch President and Chief Executive Officer.
“Lee brings leadership experience and management skills that will be critical to the company’s success as it advances two lead programs in gout and rheumatoid arthritis into late stage clinical development,” said Arlene Morris, chair of Nuon Therapeutics’ Board of Directors.
Ms. Rauch’s career spans key executive functions including corporate development, corporate finance, product development and strategic marketing. Recently, she held the position of acting head of corporate development for Onyx Pharmaceuticals. She also served as chief business officer at Point Biomedical and at Onyx. Previously, Ms. Rauch was senior vice president of corporate development at COR Therapeutics and responsible for the $2 billion merger with Millennium Pharmaceuticals. Earlier in her career, she was a member of the senior management team responsible for the merger and integration of Syntex Corporation with Hoffman-La Roche. She was also a management consultant for McKinsey & Company.
“This is an exciting time to join Nuon given the stage and the clinical profile of its lead programs,” said Ms. Rauch. “We have the opportunity to advance these oral agents and potentially improve the quality of life for millions of RA and gout patients.”
About Nuon Therapeutics, Inc.
Nuon Therapeutics, Inc. is a privately held, clinical stage, biopharmaceutical company that is developing small molecule drugs to address critical, unmet medical needs in autoimmune and rheumatic diseases. The Company was founded in 2006 and has raised a total of $38 million from investors including Domain Associates, L.L.C., Frazier Healthcare Ventures, and GBS Venture Partners. Nuon Therapeutics, Inc. has its headquarters in San Mateo, CA. For additional information, please visit: www.nuontherapeutics.com.
Source: Nuon Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.